USPTO serial 79343517
JENDII
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- VAGHANI, MAYUR C
- Law office
- TMO LAW OFFICE 124 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with JENDII?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Anti-bacterial pharmaceutical preparations; barks for pharmaceutical purposes; biological preparations for pharmaceutical purposes; capsules for pharmaceutical purposes; capsules for veterinary pharmaceutical preparations; chemical preparations containing enzymes for pharmaceutical purposes; chemical preparations for pharmaceutical purposes; chemical products for pharmaceutical use; chemicals for pharmaceutical use; decoctions for pharmaceutical purposes; decongestive pharmaceutical preparations being inhalants; digestives for pharmaceutical purposes; effervescent pharmaceutical preparations; effervescent analgesic pharmaceutical preparations; extracts of plants in capsule form (for pharmaceutical use); hormone preparations for pharmaceutical use; lotions for pharmaceutical purposes; medical foodstuff additives for pharmaceutical use; modified starches for pharmaceutical purposes; moist paper hand towels impregnated with a pharmaceutical lotion; moist wipes impregnated with a pharmaceutical lotion; moistened paper tissues impregnated with a pharmaceutical lotion; natural pharmaceutical products; natural starches for pharmaceutical purposes; oils for pharmaceutical purposes; pain killers (pharmaceuticals); pharmaceutical appetite suppressants; pharmaceutical creams; pharmaceutical preparations being antiulceratives; pharmaceutical preparations being antacids; pharmaceutical preparations; pharmaceutical preparations being hormone preparations for human use; pharmaceutical preparations containing essential oils; pharmaceutical preparations containing vitamins; pharmaceutical preparations containing royal jelly; pharmaceutical preparations for alleviating disorders of the brain; pharmaceutical preparations for animals; pharmaceutical preparations for application to the skin; pharmaceutical preparations for assisting the prevention of bone diseases; pharmaceutical preparations for enteral administration; pharmaceutical preparations for health care; pharmaceutical preparations for human use; pharmaceutical preparations for oral use; pharmaceutical preparations for personal use; pharmaceutical preparations for skin care; pharmaceutical preparations for the prevention of bone conditions; pharmaceutical preparations for the relief of insect bites; pharmaceutical preparations for the relief of insect stings; pharmaceutical preparations for the therapeutic treatment of diabetes mellitus; pharmaceutical preparations for the topical treatment of dermatological disorders; pharmaceutical preparations for the treatment of blackheads; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of depressive illness; pharmaceutical preparations for the treatment of dermatological disorders; pharmaceutical preparations for the treatment of digestive maladies; pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations for the treatment of disorders of the gastro-enterological tract; pharmaceutical preparations for the treatment of gastric diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of gynaecological disorders; pharmaceutical preparations for the treatment of joint related diseases; pharmaceutical preparations for the treatment of pimples; pharmaceutical preparations for the treatment of premenstrual tension; pharmaceutical preparations for the treatment of psoriasis; pharmaceutical preparations for the treatment of psoriasis in human beings; pharmaceutical preparations for the treatment of spots; pharmaceutical preparations for the treatment of the eyes; pharmaceutical preparations for topical use; pharmaceutical preparations for use as laxative; pharmaceutical preparations for use in gynaecology; pharmaceutical preparations for use in the treatment of arthritis; pharmaceutical preparations for use in the treatment of arthrosis; pharmaceutical preparations for use in the treatment of colostomy patients; pharmaceutical preparations for use in the treatment of hormonal disorders; pharmaceutical preparations for use in the treatment of ileostomy patients; pharmaceutical preparations for use in the treatment of muscle tension; pharmaceutical preparations for use in the treatment of pimples; pharmaceutical preparations for use in the treatment of rheumatism; pharmaceutical preparations for use in the treatment of sciatica; pharmaceutical preparations for use in the treatment of skin blemishes; pharmaceutical preparations for use in the treatment seborrheic dermatitis; pharmaceutical preparations for use in with an automated bacterial protection; pharmaceutical preparations for veterinary use; pharmaceutical preparations in the form of tablets; pharmaceutical products; pharmaceutical products derived from natural sources; pharmaceutical products for combating metabolism disorders; pharmaceutical products for metabolic disorders; pharmaceutical products for the central nervous system; pharmaceutical products for the stimulation of growth; pharmaceutical products for the treatment of blood circulation diseases; pharmaceutical products for the treatment of dysfunctions of metabolism; pharmaceutical products for the treatment of gastrointestinal disorders; pharmaceutical products for the treatment of osteoporosis; pharmaceutical products for use by humans; pharmaceutical products in gel form; pharmaceutical products in the nature of anthelmintic preparations; pharmaceutical solutions for topical irrigation purposes; pharmaceutical substances; pharmaceutical sweets; pharmaceutical tablets; pharmaceutical tonic preparations; plant extracts for pharmaceutical purposes; plant extracts for pharmaceutical use; preparations for application to the body (pharmaceuticals); preparations for application to the skin (pharmaceuticals); preparations for body care (pharmaceuticals); preparations of plants for pharmaceutical use; tablets (pharmaceuticals); topical pharmaceutical compositions; transdermal patches containing pharmaceutical preparations for application to the skin; transdermal patches for administering pharmaceuticals; wipes (tissues) impregnated with pharmaceutical lotions | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 17, 2024 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 29, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 27, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 25, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 6, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 6, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 26, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 26, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 26, 2023 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 1, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 12, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 12, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 3, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 2, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 1, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 17, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 12, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 6, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 5, 2022 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jun 30, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |